Eczema herpeticum.  Presentation of a typical case  associated with atopic dermatitis  and brief review of current events  on the pathophysiology

Gustavo Armando Gómez Meléndez; Larissa Dorina López Cepeda

2014, Number 2

<< Back Next >>

Rev Cent Dermatol Pascua 2014; 23 (2)

Eczema herpeticum. Presentation of a typical case associated with atopic dermatitis and brief review of current events on the pathophysiology

López CLD, Gómez MGA

Full text

How to cite this article

Language: Spanish
References: 21
Page: 59-62
PDF size: 222.72 Kb.

ABSTRACT

Eczema herpeticum, also known as Kaposi’s varicelliform eruption, is a disseminated expression by the herpes simplex virus infection. It tends to arise from a pre-existing skin disease, usually atopic dermatitis. In this article we report the case of a fifteen years old male patient, with eczema herpeticum associated with atopic dermatitis with a good response to antiviral treatment, and we made a review of the new aspects in eczema herpeticum physiopathology.

REFERENCES

Marques A, Straus SE. Herpes simplex. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick’s dermatology in general medicine. 7th Ed. New York; McGraw-Hill, 2008, pp. 1873-1883.
Mir-Bonafé JM, Román-Curto C, Santos-Briz A, Palacios-Álvarez I, Santos-Durán JC, Fernández-López E. Eczema herpeticum with herpetic folliculitis after bone marrow transplant under prophylactic acyclovir: are patients with underlying dermatologic disorders at higher risk? Transpl Infect Dis. 2013; 15: 75-80.
Gupta M, Huang V, Linette G, Cornelius L. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption. Arch Dermatol. 2012; 148: 966-968.
Lübbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology. 2000; 201: 249-251.
Segura S, Romero D, Carrera C, Iranzo P, Estrach T. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Derm Venereol. 2005; 85: 524-525.
Osawa K, Etoh T, Ariyoshi N, Ishii I, Ohtani M, Kariya S, Uchino K, Kitada M. Relationship between Kaposi’s variceliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region. J Dermatol. 2007; 34: 531-536.
Kimata H. Kaposi’s varicelliform eruption associated with the use of tacrolimus ointment in two neonates. Indian J Dermatol Venereol Leprol. 2008; 74: 262-263.
Marín E, Eng A, Velázquez E. Erupción variceliforme de Kaposi, presentación de un caso. Rev Cent Dermatol Pascua. 2005; 14: 31-34.
Leung D. Why is eczema herpeticum unexpectedly rare? Antiviral Res. 2013; 98: 153-157.
Gao PS, Leung DY, Rafaels NM, Boguniewicz M, Hand T, Gao L et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J Invest Dermatol. 2012; 132: 650-657.
Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009; 124: 260-269.
Haapakoski R, Karisola P, Fyhrquist N, Savinko T, Lehtimäki S, Wolff H et al. Toll-like receptor activation during cutaneous allergen sensitization blocks development of asthma through IFN-gamma-dependent mechanisms. J Invest Dermatol. 2013; 133: 964-972.
Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC et al. Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Invest Dermatol. 2013; 133: 988-998.
Gao PS, Rafaels NM, Hand T et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol. 2009; 124: 507-513.
Benedetto A, Slifka MK, Rafaels NM, Kuo IH, Georas SN, Boguniewicz M et al. Reductions in Claudin-1 may enhance susceptibility to HSV-1 infections inatopic dermatitis. J Allergy Clin Immunol. 2011; 128: 242-246.
Bin L, Kim BE, Brauweiler A, Goleva E, Streib J, Ji Y et al. Staphylococcus aureus α-toxin modulates skin host response to viral infection. J Allergy Clin Immunol. 2012; 130: 683-691.
Lübbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology. 2000; 201: 249-251.
Ambo M. Relapsing Kaposi’s varicelliform eruption and herpes simplex following facial tacrolimus treatment for atopic dermatitis. Acta Derm Venereol. 2002; 82: 224-225.
Segura S, Romero D, Carrera C, Iranzo P, Estrach T. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Derm Venereol. 2005; 85: 524-525.
Kimata H. Kaposi’s varicelliform eruption associated with the use of tacrolimus ointment in two neonates. Indian J Dermatol Venereol Leprol. 2008; 74: 262-263.
Kim M, Jung M, Hong SP, Jeon H, Kim MJ, Cho MY et al. Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function. Exp Dermatol. 2010; 19: 501-510.